ArticleThe European respiratory journal2021
A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD.
Article in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 79 citations in OpenAlex.
- Review
- The gut mycobiome and inter-kingdom microbial networks are linked to COPD severity in lung cancer patients.Scientific reports · 2026Article
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Differences in Clinical Characteristics of AECOPD Patients with or withoutInternational journal of chronic obstructive pulmonary disease · 2026Article
- Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease.EBioMedicine · 2026Observational
- The airway mycobiome in chronic respiratory diseases: current advances and future frontiers.Journal of translational medicine · 2025Review
- [Research Progress on the Regulatory Mechanism of Respiratory Microbiota in the Comorbidity of Chronic Obstructive Pulmonary Disease and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Clinical application of single-cell RNA sequencing in disease and therapy.Clinical and translational medicine · 2025Review
- Aspergillus sensitisation & allergic bronchopulmonary aspergillosis in chronic obstructive pulmonary disease: Redefining a treatable trait.The Indian journal of medical research · 2025Article
- Airway Candida diversity in COPD patients and its differential stimulatory effects on lung inflammation in mice.BMC pulmonary medicine · 2025Article
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- Distinct airway mycobiome signature in patients with pulmonary hypertension and subgroups.BMC medicine · 2025Article
- Lung Microbiota: From Healthy Lungs to Development of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Review
- Mycobiome analyses of critically ill COVID-19 patients.Microbiology spectrum · 2025Article
- The fungal microbiota modulate neonatal oxygen-induced lung injury.Microbiome · 2025Article
- Airway Microbiota Profiles in Children With and Without Asthma: A Comparative Study.Journal of asthma and allergy · 2025Article
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- Correlation ofInternational journal of chronic obstructive pulmonary disease · 2025Article
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe chronic obstructive pulmonary disease (COPD) bacteriome associates with disease severity, exacerbations and mortality. While COPD patients are susceptible to fungal sensitisation, the role of the fungal mycobiome remains uncertain.
methodsWe report the largest multicentre evaluation of the COPD airway mycobiome to date, including participants from Asia (Singapore and Malaysia) and the UK (Scotland) when stable (n=337) and during exacerbations (n=66) as well as nondiseased (healthy) controls (n=47). Longitudinal mycobiome analysis was performed during and following COPD exacerbations (n=34), and examined in terms of exacerbation frequency, 2-year mortality and occurrence of serum specific IgE (sIgE) against selected fungi.
resultsA distinct mycobiome profile is observed in COPD compared with controls as evidenced by increased α-diversity (Shannon index; p<0.001). Significant airway mycobiome differences, including greater interfungal interaction (by co-occurrence), characterise very frequent COPD exacerbators (three or more exacerbations per year) (permutational multivariate ANOVA; adjusted p<0.001). Longitudinal analyses during exacerbations and following treatment with antibiotics and corticosteroids did not reveal any significant change in airway mycobiome profile. Unsupervised clustering resulted in two clinically distinct COPD groups: one with increased symptoms (COPD Assessment Test score) and
conclusionThe airway mycobiome in COPD is characterised by specific fungal genera associated with exacerbations and increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.